October 15, 2024

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH
Go back

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
aimed analytics secures six-digit first funding and acquires ValueData GmbH

aimed analytics secures six-digit first funding and acquires ValueData GmbH

aimed analytics GmbH has successfully closed its first funding round, raising a six-digit investment. At the same time, the company has completed the acquisition of ValueData GmbH, further strengthening its position as a pioneer in AI-driven biomedical data analytics. “Our mission is clear: to shape the future of medicine through the power of data analytics. […]

read more
After EMBL: Umlaut.bio and its potential role in drug development

After EMBL: Umlaut.bio and its potential role in drug development

Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease. With just two dots above a letter, the German umlaut can instantly change a word’s pronunciation, its quantity (singular to plural), or even its […]

read more
Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

Chordomas are rare bone tumors for which there are currently no effective drugs. A research team from the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the central driver of tumor development. In the result, they slowed the growth […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp